Delivery Order 75N93022D00003-75N93024F00001
Award Date 8/31/24
Potential Completion Date 8/27/28
Potential Value $5.9M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Durham, NC 27708, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Duke University has been awarded a cost-no-fee task order valued at $10.38 million by the National Institutes of Health National Institute of Allergy and Infectious Diseases. The task order was issued against Duke University's existing preclinical and translational vaccine development IDIQ with the agency. Under this task order, Duke University will provide services and materials to support in vitro transcription reactions, mRNA purification, and procurement of lipid raw materials for...
- Duke University's Office of Research Administration was awarded a delivery order contract by the National Institute of Allergy and Infectious Diseases (NIAID) for research and development product storage and shipping support related to preclinical and translational vaccine development for HIV and other candidate agents. The contract, awarded on December 1, 2021, carries a ceiling value of approximately $3.96 million and extends through November 30, 2028. This is a cost-plus-no-fee delivery order...
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on September 20, 2016, with a ceiling value of $1.572 million for purification of HIV envelope proteins using an immunoaffinity-based process.</p> <p>Work is performed in New York, NY. The order was priced on a cost-plus-fixed-fee basis and carried an ultimate completion date of June 15, 2020. The award included de-obligation of remaining FY 2017 funds.</p>
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on September 14, 2017, with a ceiling value of $432,452.00 for a feasibility assessment of HIV envelope protein antigens to de-obligate remaining 2017 funds.</p> <p>Place of performance is New York, NY. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of October 31, 2018. No set-aside was used.</p>
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Advanced Bioscience Laboratories, Inc. on September 25, 2014, with a ceiling value of $494,513.97, for preclinical development support including expression and production of HIV-1 envelope protein.</p> <p>Place of performance is Rockville, MD. The delivery order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of September 25, 2017. No set-aside was used.</p>
- This task order funds the guaranteed minimum amount under a preexisting master indefinite-delivery/indefinite-quantity contract between the National Institutes of Health's National Institute of Allergy and Infectious Diseases and Advanced Bioscience Laboratories, Inc. The purpose is to support preclinical and translational vaccine development for HIV and other candidate agents. The $2,500 delivery order was awarded on December 1, 2021 with a one-year period of performance ending November 30,...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Duke University on December 15, 2019, under the Therapeutics Against Infectious Diseases Phase 1 IDIQ for establishment and operation of a Phase 1 clinical trial unit supporting therapeutic development against infectious diseases. The parent IDIQ supports pediatric drug development including expert team establishment, clinical protocol development, preclinical studies, formulation work, and execution of Phases...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Advanced Bioscience Laboratories, Inc., on June 10, 2017, with a ceiling value of $804,692 for long-term stability testing of a nanoparticle-based HIV envelope-containing vaccine under NIAID preclinical development support. Place of performance is Rockville, Maryland. The order extends through June 9, 2029, and carries cost-plus-fixed-fee pricing with no set-aside designation. Government invoicing across...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on May 15, 2018, with a ceiling value of $55,936.00 under a Cost Plus Fixed Fee pricing structure. Place of performance is New York, NY. The ultimate completion date is May 14, 2019. The delivery order funds base task order work designated as OBRA-2, supporting vaccine development and related services within IAVI's research and development portfolio for infectious...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Dynport Vaccine Company LLC on June 13, 2017, with a ceiling value of $3.86 million under the Therapeutics Against Infectious Diseases Phase 1 parent IDIQ for Phase 1 clinical trial services. The order funds Phase 1 clinical trial unit operations and study task area B activities supporting therapeutics development against infectious diseases. Place of performance is Durham, North Carolina. The award carries a...